Yue Hu

Yue Hu

Auto-generated profile, based on publicly available information

Yue Hu

Department of Paediatric Genetics, Endocrinology and Metabolism, Chengdu Women’s and Children’s Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2017 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Closed access
PDF file
YHY. Hu
Y. Hu
ZLZ. Li
Z. Li
DMD.-H. Mi
D.-H. Mi
NCN. Cao
N. Cao
SZS.-W. Zu
S.-W. Zu
YQY. Qu
Y. Qu
Hyperthermia is an effective treatment modality that augments the anticancer effects of radiotherapy and chemotherapy. Hyperthermia–chemo-radiotherapy (HCRT) is a combination therapy that can strengthen anticancer effects through a synergistic interaction between heat, chemotherapy and radiation. Here, we carried out a systematic review and meta-analysis to evaluate the clinical efficacy and safety of chemoradiation combined with regional hyperthermia (HCRT) for oesophageal carcinoma. We conducted computer searches of foreign databases, including Cochrane Library, PubMed, EMBASE, Web of Science and Chinese databases, including CBM, CNKI and WanFang; we also retrieved other sources as supplement. All relevant randomized controlled trials (RCTs) were collected to compare HCRT and other therapies, including chemotherapy combined with radiotherapy (CRT) and radiotherapy alone (RT). After literature screening, data extraction and quality evaluation performed by appropriate criteria, the meta-analyses were conducted using RevMan 5.1 software (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). Nineteen RCTs were included, comprising 1519 patients. Meta-analysis showed that the 1-, 3-, 5- and 7-year survival, complete response and total effective rates of the HCRT group were higher than those of the CRT group; the rates of gastrointestinal reaction, leucocytopenia and radiation oesophagitis in the HCRT group were lower than those of the CRT group, indicating significant differences (P < 0·05). The 1-, 2-, 3- and 5-year survival, complete response and total effective rates of the HCRT group were higher than those of the RT group, the recurrence and distant metastasis rates of the HCRT group were lower than those of the RT group, and there were significant differences in all of the indicators (P < 0·05). This is the first systematic review and meta-analysis to evaluate HCRT for oesophageal carcinoma. Compared with CRT or RT, HCRT can improve long-term and short-term curative effects; it is also safe and feasible. Additional high-quality and large sample size RCTs will be necessary to further demonstrate the long-term survival benefits and comprehensive safety profile of HCRT.

23 September 2024 in Journal of Hepatology
Verified
Journal Article
Closed access
ZLZheng Li
Zheng Li
ZLZhiping Li
Zhiping Li
DCDan Cao
Dan Cao
YHYue Hu
Yue Hu

21 October 2024 in Journal of Hepatology
Verified
Journal Article
Closed access
ZLZheng Li
Zheng Li
YSYali Shen
Yali Shen
ZLZhiping Li
Zhiping Li
DCDan Cao
Dan Cao
YHYue Hu
Yue Hu

24 July 2024 in Hepatology
Verified
Journal Article
Closed access
YHYue Hu
Yue Hu
ZLZheng Li
Zheng Li
ZLZhiping Li
Zhiping Li
YZYaqin Zhao
Yaqin Zhao
QLQing Liu
Qing Liu
XCXinran Cheng
Xinran Cheng
An abstract is unavailable. This article is available as a PDF only.

11 May 2023 in Hepatology
Verified
Journal Article
Closed access
YHYue Hu
Yue Hu
ZLZheng Li
Zheng Li
WHWeilan He
Weilan He
XWXin Wang
Xin Wang
XCXinran Cheng
Xinran Cheng
An abstract is unavailable. This article is available as a PDF only.